Dynamics of hemostasis system and c-reactive protein indexes while new oral anticoagulants intake in patients after hip joint endoprosthesis replacement


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Indirect oral anticoagulants use in some cases may be accompanied by an increased risk of bleeding in patients after orthopedic traumatological operations. The aim of the study was to compare coagulological, biochemical and hematological laboratory parameters while rivaroxaban and apixaban intake in patients after hip arthroplasty (HA) operation. Material and methods. 38 patients aged 58±15 (33-85) years with hip joint osteoarthritis diagnosis were involved in the study. Laboratory study included the measiring of hemostasis parameters, biochemical parameters and hematological parameters on the analyzer. Rivaroxaban and apixaban concentration was measured in blood plasma using an ACL TOP 500CTS analyzer (Werfen, USA) on the 1st day after surgery and on the 7th day after HA. Results. In patients receiving rivaroxaban, on the first day after HA, the average Cmax value of rivaroxaban in blood plasma was 122,4 (94-178) ng/ml, at discharge from the hospital - 186,47 (152,8239) ng/ml, which corresponded to the therapeutic intervals. In patients using apixaban, similar indexes were 60,3 (14-95,2) and 79,85 (14-196,4) ng/ml, which also corresponded to the therapeutic intervals. While taking rivaroxaban, patients showed a statistically significant increase in INR (p <0,05), in contrast to the group of patients receiving apixaban. Conclusion. Intake of rivaroxaban and apixaban in patients with hip joint osteoarthritis during HA was not accompanied by hemorrhagic complications. Patients in the apixaban group had higher markers of inflammation than in the rivaroxaban group. Taking into account the data obtained during this work when comparing hemostasis and C-reactive protein indexes, it is more preferable to take rivaroxaban in order to reduce the inflammatory response.

Негізгі сөздер

Толық мәтін

Рұқсат жабық

Авторлар туралы

Ksenia Zamyatina

I.I. Mechnikov North-Western State Medical University of the Ministry of Healthcare of Russia

postgraduate student at the Department of biological and general chemistry named after V.V. Sokolovsky

Sergey Saiganov

I.I. Mechnikov North-Western State Medical University of the Ministry of Healthcare of Russia

MD, professor, rector

Vadim Mazurov

I.I. Mechnikov North-Western State Medical University of the Ministry of Healthcare of Russia

Email: maz.nwgmu@yandex.ru
MD, professor, academician of RAS, Chief scientific consultant, head of the Department of therapy, rheumatology, temporary disability and medical care quality examination named after E.E. Eichwald

Larisa Gaykovaya

I.I. Mechnikov North-Western State Medical University of the Ministry of Healthcare of Russia

MD, associate professor, head of the Department of biological and gleneral chemistry named after V.V. Sokolovsky

Alexander Tkachenko

I.I. Mechnikov North-Western State Medical University of the Ministry of Healthcare of Russia

MD, professor, professor of the Department of traumatology, orthopedics and mlilitary field surgery

Irina Urazovskaya

I.I. Mechnikov North-Western State Medical University of the Ministry of Healthcare of Russia

PhD, assistant of the Department of hospital surgery and cardiologynamed after M.S. Kushakovsky

Dzhalolidin Mansurov

I.I. Mechnikov North-Western State Medical University of the Ministry of Healthcare of Russia

PhD, assistant at the Department of traumatology, orthopedics and military field surgery

Valery Khaidarov

I.I. Mechnikov North-Western State Medical University of the Ministry of Healthcare of Russia

PhD, associate professor of the Department of traumatology, orthopedics and military field surgery

Alexander Balgley

I.I. Mechnikov North-Western State Medical University of the Ministry of Healthcare of Russia

assistant at the Department of traumatology, orthopedics and military field surgery

Әдебиет тізімі

  1. Ortel T.L., Neumann I., Ageno W. et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: Treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020; 4(19): 4693-738. doi: 10.1182/ bloodadvances.2020001830.
  2. Samama M.M., Martinoli J-L., LeFlem L. et al. Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor. Thromb Haemost. 2010; 103(4): 815-25. doi: 10.1160/TH09-03-0176.
  3. Christersson C., Oldgren J., Wallentin L., Siegbahn A. Treatment with an oral direct thrombin inhibitor decreases platelet activity but increases markers of inflammation in patients with myocardial infarction. J. Intern Med. 2011; 270(3): 215-23. doi: 10.1111/j.1365-2796.2011.02354.x.
  4. Tamigniau A., Douxfils J., Nicolas J-B. et al. [Why, when and how to monitor new oral anticoagulants]. Rev Med Suisse. 2014; 10(416): 326-33.
  5. Ревишвили А.Ш., Шляхто Е.В., Замятин М.Н. с соавт. Особенности оказания экстренной и неотложной медицинской помощи пациентам, получающим прямые оральные антикоагулянты. Согласительный документ междисциплинарной группы экспертов. Вестник аритмологии. 2018; 92: 59-72. [Revishvili A.Sh., Shlyakhto E.V., Zamyatin M.N. et al. Features of the provision of emergency and urgent medical care to patients receiving direct oral anticoagulants. Consensus document of the interdisciplinary expert group. Vestnik aritmologii = Herald of Arrhythmology. 2018; 92: 59-72 (In Russ.)]. https://dx.doi.org/10.25760/VA-2018-92-59-72.
  6. Lindhoff-Last E., Samama M.M., Ortel T.L. et al. Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit. 2010; 32(6): 673-79. doi: 10.1097/FTD.0b01381f2f264.
  7. Douxfils J., Ageno W., Samama C-M. et al. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J. Thromb Haemost. 2018; 16(2): 209-19. doi: 10.1111/jth.13912.
  8. Сычев Д.А., Синицына И.И., Цомая И.В. с соавт. Клинико-фармакологическое и клиническое обоснование кратности применения новых пероральных антикоагулягтов. Кардиология. 2017; 11: 84-93. [Sychev D.A., Sinitsyna I.I., Tsomaya I.V. et al. Clinical, pharmacological and clinical substantiation of the frequency of use of new oral anticoagulants. Kardiologiya = Cardiology. 2017; 11: 84-93 (In Russ.)]. https://dx.doi.org/10087/cadio.2017/11/10058.
  9. Cuker A., Siegal D.M., Crowther M.A., Garcia D.A. Laboratory measurement of the anticoagulant activity of the non-vitamin K. oral anticoagulants. J. Am Coll Cardiol. 2014; 64(11): 1128-39. doi: 10.1016/j.jacc.2014.05.065.
  10. Spyropoulos A.C., Al-Badri A., Sherwood M.W., Douketis J.D. To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: Comment. J. Thromb Haemost. 2016; 14(12): 2556-59. doi: 10.1111/jth.13505.
  11. Highcock A.J., As-Sultany M., Finley R., Donnachie N.J. A Prospective cohort comparative study of rivaroxaban, dabigatran, and apixaban oral thromboprophylaxis in 2431 hip and knee arthroplasty patients: Primary efficacy out-comes and safety profile. J. Arthroplasty. 2020; 35(11): 3093-98. doi: 10.1016/j.arth.2020.06.032.
  12. Connors J.M. Testing and monitoring direct oral anticoagulants. Blood. 2018; 132(19): 2009-15. doi: 10.1182/blood-2018-04-791541.
  13. Battistelli S., Fortina M., Carta S. et al. Serum C-reactive protein and procalcitonin kinetics in patients undergoing elective total hip arthroplasty. Biomed Res Int. 2014; 2014: 565080. doi: 10.1155/2014/565080.
  14. Jiang Y., Li J., Liu Y. et al. Risk factors for deep vein thrombosis after orthopedic surgery and the diagnostic value of D-dimer. Ann Vasc Surg. 2015; 29(4): 675-81. doi: 10.1016/j.avsg.2014.12.022.
  15. Paruk F., Chausse J.M. Monitoring the post surgery inflammatory host response. J. Emerg Crit Care Med. 2019; 3: 47. doi: 10.21037/ jeccm.2019.08.06.
  16. Poredos P., Poredos P., Jezovnik M.K. et al. Time course of inflammatory and procoagulant markers in the early period after total hip replacement. Clin Appl Thromb Hemost. 2021; 27: 1076029620985941. doi: 10.1177/1076029620985941.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2021

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>